What type of study is this?

This is a In Vitro Study study.

December 8, 2025Blood

High dose ascorbate downregulates innate immune cytokines in the bone marrow of TET2 mutant chronic myelomonocytic leukemia

View Full Paper

Ask AI

Bookmark

Authors

DRDavid RossSouth Australia Pathology AYAgnes S. M. YongThe University of Sydney DTDaniel C. ThomasWomen's and Children's Health Network

Discussion

Member takes

Implication

Observational analysis reveals high dose ascorbate reduces IL-1β and GM-CSF in TET2 mutant chronic myelomonocytic leukemia patients, indicating potential for new therapies.

Key Points

Treatment with high dose ascorbate resulted in multiple fold reductions in innate immune cytokines, including IL-1β and GM-CSF.
Cytokine profiling showed significant decreases in key inflammatory markers over several treatment cycles in the trial.
Assessment using cytokine profiling demonstrated that TET2 mutations correlate with increased IL-1β in response to immune challenges.
Findings suggest that high dose ascorbate may down regulate innate immune responses linked to chronic myelomonocytic leukemia.

Cite This Study

Ross et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7ae https://doi.org/10.1182/blood-2025-2065

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis reveals high dose ascorbate reduces IL-1β and GM-CSF in TET2 mutant chronic myelomonocytic leukemia patients, indicating potential for new therapies.

High dose ascorbate downregulates innate immune cytokines in the bone marrow of TET2 mutant chronic myelomonocytic leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

High dose ascorbate downregulates innate immune cytokines in the bone marrow of TET2 mutant chronic myelomonocytic leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider